Cynosure Inc (CYNO) 10-Q Quarterly Report November 2016


Timothy Baker		Scott Solomon
Chief Financial Officer		Senior Vice President
Cynosure, Inc.		Sharon Merrill Associates
(978) 256-4200		(617) 542-5300

tbaker@cynosure.com		CYNO@investorrelations.com

Cynosure Announces Record Third-Quarter Revenues; Revenues Increase 36 Percent from Prior Year to $106.4 Million

Third-Quarter 2016 Highlights:

•

North American product revenue up 43 percent to $58.2 million

•

International product revenue up 23 percent to $29.4 million

•

Revenue from parts, service and disposables up 45 percent for the quarter to $18.7 million

•

GAAP gross margin up 240 basis points to 59.0 percent; Non-GAAP gross margin up 180 basis points to 60.4 percent

•

GAAP earnings of $0.17 per diluted share; Non-GAAP earnings of $0.29 per diluted share

Westford, MA, October 25, 2016

– Cynosure, Inc. (NASDAQ: CYNO) today reported revenues for the three months ended September 30, 2016 of $106.4 million, an increase of 36 percent from $78.4 million in the third quarter of 2015. Third-quarter 2016 net income of $4.2 million, or $0.17 per diluted share, represented an increase of 29 percent compared with $3.2 million, or $0.14 per diluted share, for the same period of 2015. On a non-GAAP basis, excluding non-cash unrealized foreign exchange measurement gains and losses and amortization of intangibles, third-quarter net income increased 43 percent to $7.0 million, or $0.29 per diluted share, compared with $4.9 million, or $0.21 per diluted share, for the prior-year period.

Operating income for the 2016 third quarter was $8.2 million, compared with third-quarter 2015 operating income of $4.8 million. On a non-GAAP basis, excluding amortization of intangibles, income from operations for the third quarter of 2016 was $10.3 million, compared with $7.1 million for the prior-year period.

Michael Davin, Cynosure President and CEO, said, “We delivered a solid operating and financial performance, generating record third-quarter revenue, profitable sales growth, expanded margins and positive operating cash flow. Product revenue in our North American and international sales channels saw double-digit percentage gains in the third quarter, which marked our 27^th consecutive quarter of year-over-year top-line growth.

The following information was filed by Cynosure Inc (CYNO) on Tuesday, October 25, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/885306/000119312516761640/d212420d10q.htm

View differences made from one quarter to another to evaluate Cynosure Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Cynosure Inc.

Continue

Assess how Cynosure Inc's management team is paid from their Annual Proxy

Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Cynosure Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: CYNO
CIK: 885306
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-16-761640
Submitted to the SEC: Mon Nov 07 2016 4:06:54 PM EST
Accepted by the SEC: Mon Nov 07 2016
Period: Friday, September 30, 2016
Industry: Electromedical And Electrotherapeutic Apparatus